Business Context and Reporting Period
Company: Radiopharm Theranostics Ltd
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month ended September 30, 2025
Principal Office: Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
The filing serves to disclose a public announcement made to the Australian Securities Exchange regarding a new strategic partnership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
The primary material change disclosed is the establishment of a research partnership with Starpharma, as detailed in the attached Public Notice.
Guidance, Outlook, and Risks
Management Commentary: The filing references an announcement titled "Radiopharm Theranostics Partners with Starpharma on Research."
Risks and Contingencies: The filing text does not provide specific details regarding risks, contingencies, or unusual items associated with the partnership. The report explicitly states it is not deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review the full text of the attached Public Notice (Exhibit 99.1) for specific terms of the Starpharma research partnership.
- Verify the strategic fit and potential commercial impact of the collaboration on Radiopharm's theranostics pipeline.
- Check for subsequent filings that may provide financial implications or milestones related to this agreement.